Disclosed is the use of an effective amount of liposomal amikacin in the preparation of a medicament for the treatment of a pulmonary disorder in a patient, wherein the medicament comprises amikacin and a lipid component comprising a phospholipid and a sterol, and the medicament is for administration to the patient via inhalation for at least two treatment cycles, wherein the treatment cycle comprises an administration period of the medicament of 15 to 75 days, followed by an off period of 15 to 75 days ； and the effective dose of the medicament comprises 100 to 2500 mg of amikacin daily during the administration period , and wherein the medicament is for administration to the patient by nebulisation.
